Evidence map›Paper›PMID 32493412›Full record

ArticleClinical epigenetics2020

Genome-wide analysis of DNA methylation identifies S100A13 as an epigenetic biomarker in individuals with chronic (≥ 30 years) type 2 diabetes without diabetic retinopathy.

Tao Li, Yi Xu, Yongyong Shi, Jianhua Chen, Senlin Lin, Jianfeng Zhu, Xian Xu, Lina Lu, Haidong Zou

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical epigenetics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Tao LiShanghai Eye Diseases Prevention & Treatment Center/Shanghai Eye Hospital, No. 380, Kangding Road, Shanghai, 200040, China.
Yi XuShanghai Eye Diseases Prevention & Treatment Center/Shanghai Eye Hospital, No. 380, Kangding Road, Shanghai, 200040, China.
Yongyong ShiBio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), the Collaborative Innovation Center for Brain Science, Shanghai Jiaotong University, Shanghai, China.
Jianhua ChenShanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Senlin LinShanghai Eye Diseases Prevention & Treatment Center/Shanghai Eye Hospital, No. 380, Kangding Road, Shanghai, 200040, China.
Jianfeng ZhuShanghai Eye Diseases Prevention & Treatment Center/Shanghai Eye Hospital, No. 380, Kangding Road, Shanghai, 200040, China.
Xian XuShanghai Eye Diseases Prevention & Treatment Center/Shanghai Eye Hospital, No. 380, Kangding Road, Shanghai, 200040, China.
Lina LuShanghai Eye Diseases Prevention & Treatment Center/Shanghai Eye Hospital, No. 380, Kangding Road, Shanghai, 200040, China.
Haidong ZouShanghai Eye Diseases Prevention & Treatment Center/Shanghai Eye Hospital, No. 380, Kangding Road, Shanghai, 200040, China. zouhaidong@sjtu.edu.cn.ORCID 0000-0002-6831-7560
Shanghai Eye Disease Prevention & Treatment Center · CNShanghai Jiao Tong University · CNShanghai Mental Health Center · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study aimed to determine the epigenetic biomarkers of diabetic retinopathy (DR) in subjects with type 2 diabetes mellitus (T2DM). This retrospective study is based on the Shanghai Xinjing community prevention and treatment administrative system of chronic diseases. The subjects enrolled herein were T2DM patients who had undergone long-term follow-up evaluation in the system. Two consecutive studies were conducted. In the discovery cohort, among 19 subjects who had developed DR with a DM duration < 3 years and 21 subjects without DR > 30 years after being diagnosed with DM, an Infinium Human Methylation 850 Beadchip was used to identify differential methylation regions (DMRs) and differential methylation sites (DMSs). The function of the genes was assessed through KEGG enrichment analysis, Gene Ontology (GO) analysis, and pathway network analysis. In the replication cohort, 87 DR patients with a short DM duration and 89 patients without DR over a DM duration > 20 years were compared to assess the association between DMSs and DR upon pyrosequencing.

resultsA total of 34 DMRs were identified. Genes containing DMSs with the top 5 highest beta value differences between DR and non-DR participants were located on chromosome 1 and were present in the S100A13 gene, which was associated with 71 GO terms. Two S100A13 gene sites, i.e., cg02873163 and cg11343894, displayed a good correlation with DR on pyrosequencing.

conclusionsDMSs in the S100A13 gene may be potential biomarkers of DR.

Indexed as

AdultAgedAged, 80 and overBiomarkersCase-Control StudiesDiabetes Mellitus, Type 2Diabetic RetinopathyDNA MethylationEpigenesis, GeneticEpigenomicsFemaleFollow-Up StudiesGene OntologyGenome-Wide Association StudyHumansMaleBiomarkersS100A13 protein, humanS100 ProteinsBiomarkersDiabetic retinopathyDNA methylationS100A13T2DM

Identifiers

PMID32493412
PMCPMC7268721
OpenAlexW3037228740

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.